Author: Alexander J. Zajac
Editor: Lily Robinson
In Regeneron Pharmaceuticals, Inc. v. Merus N.V., No. 2016-1346 (Fed. Cir. July 27, 2017), the Federal Circuit affirmed the district court’s decision that the claims of U.S. Patent No. 8,502,018 were unenforceable due to Regeneron’s inequitable conduct during prosecution.
The parties agreed that there were four references known to Regeneron during prosecution that were not cited to the Patent and Trademark Office (PTO). Regeneron, however, argued that these references were neither material nor were withheld with specific intent to deceive the PTO. Continue reading